CYP2D6 and CYP2C19 Allelic Diversity in Māori from Te Tairāwhiti, New Zealand

135 CYP2D6 and 73 CYP2C19 genotypes were sequenced from Māori individuals, largely from the Ngāti Porou iwi, using targeted nanopore sequencing. The data includes inferred metaboliser phenotypes, with 54% of the cohort classified as CYP2D6 normal metabolisers and 45% as CYP2C19 intermediate metabolisers. Leonie Hitchman published this dataset on figshare in March 2026 to contribute to equitable pharmacogenetic testing in Aotearoa New Zealand.

Use Cases

• Analyzing allele frequencies for CYP2D6 and CYP2C19 based on the described cohort of 135 and 73 genotypes.
• Investigating the prevalence of the CYP2D6*71 variant and its uncertain functional impact on drug metabolism.
• Comparing metaboliser phenotype distributions (e.g., normal, intermediate) between populations.
• Supporting the development of population-specific pharmacogenetic testing guidelines based on the described genetic variation.

Strengths

• Data focuses on the understudied Māori population, specifically the Ngāti Porou iwi from Te Tairāwhiti.
• Includes inferred metaboliser phenotypes for the majority of the 135 CYP2D6 and 73 CYP2C19 sequenced genotypes.
• Uses targeted nanopore sequencing, a method for identifying genetic variants.

Limitations

• The dataset is small (120.1 KB), indicating a limited scope and sample size.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale analyses.

Provenance

Source

figshare, author Leonie Hitchman.

Collection Method

Targeted nanopore sequencing of DNA samples.

Freshness

Last updated 2026-03-18 07:35:06

Geography

Te Tairāwhiti (Gisborne), Aotearoa New Zealand, focusing on Māori individuals largely affiliated with Ngāti Porou iwi.